Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

Patricia Fellows; Jeffrey Adamovicz; Justin Hartings; Robert Sherwood; William Mega; Trevor Brasel; Ed Barr; Lou Holland; Winston Lin; Amanda Rom; William Blackwelder; Jessica Price; Stephen Morris; Doris Snow; Mary Kate Hart

doi:10.1016/j.vaccine.2010.09.062

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

Patricia Fellows, Jeffrey Adamovicz, Justin Hartings, Robert Sherwood, William Mega, Trevor Brasel, Ed Barr, Lou Holland, Winston Lin, Amanda Rom, William Blackwelder, Jessica Price, Stephen Morris, Doris Snow, Mary Kate Hart

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

Original language	English (US)
Pages (from-to)	7748-7756
Number of pages	9
Journal	Vaccine
Volume	28
Issue number	49
DOIs	https://doi.org/10.1016/j.vaccine.2010.09.062
State	Published - Nov 16 2010
Externally published	Yes

Keywords

Passive transfer
Pneumonic plague
RF1V vaccine
Yersinia pestis

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2010.09.062

Cite this

Fellows, P., Adamovicz, J., Hartings, J., Sherwood, R., Mega, W., Brasel, T., Barr, E., Holland, L., Lin, W., Rom, A., Blackwelder, W., Price, J., Morris, S., Snow, D., & Hart, M. K. (2010). Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V). Vaccine, 28(49), 7748-7756. https://doi.org/10.1016/j.vaccine.2010.09.062

Fellows, P, Adamovicz, J, Hartings, J, Sherwood, R, Mega, W, Brasel, T, Barr, E, Holland, L, Lin, W, Rom, A, Blackwelder, W, Price, J, Morris, S, Snow, D & Hart, MK 2010, 'Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)', Vaccine, vol. 28, no. 49, pp. 7748-7756. https://doi.org/10.1016/j.vaccine.2010.09.062

@article{a5a522512b6b464195f84ec0180616a4,

title = "Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)",

abstract = "Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect na{\"i}ve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into na{\"i}ve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.",

keywords = "Passive transfer, Pneumonic plague, RF1V vaccine, Yersinia pestis",

author = "Patricia Fellows and Jeffrey Adamovicz and Justin Hartings and Robert Sherwood and William Mega and Trevor Brasel and Ed Barr and Lou Holland and Winston Lin and Amanda Rom and William Blackwelder and Jessica Price and Stephen Morris and Doris Snow and Hart, {Mary Kate}",

note = "Funding Information: This study was supported by the Chemical Biological Medical Systems-Joint Vaccine Acquisition Program (CBMS/JVAP) Contract DAMD 17-98-C8024 . The current development effort for the rF1V vaccine is supported by an international partnering arrangement that includes the United Kingdom and Canada. The facilities performing the passive transfer model development studies are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. Human sera were collected under a research protocol approved by the USAMRMC Human Subjects Research Review Board and as part of an IRB- and HSRRB-approved clinical study titled, “A Phase 2(a), Dose-blinded, Block-Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers” [Protocol rFV-02(a)]. ",

year = "2010",

month = nov,

day = "16",

doi = "10.1016/j.vaccine.2010.09.062",

language = "English (US)",

volume = "28",

pages = "7748--7756",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "49",

}

TY - JOUR

T1 - Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

AU - Fellows, Patricia

AU - Adamovicz, Jeffrey

AU - Hartings, Justin

AU - Sherwood, Robert

AU - Mega, William

AU - Brasel, Trevor

AU - Barr, Ed

AU - Holland, Lou

AU - Lin, Winston

AU - Rom, Amanda

AU - Blackwelder, William

AU - Price, Jessica

AU - Morris, Stephen

AU - Snow, Doris

AU - Hart, Mary Kate

N1 - Funding Information: This study was supported by the Chemical Biological Medical Systems-Joint Vaccine Acquisition Program (CBMS/JVAP) Contract DAMD 17-98-C8024 . The current development effort for the rF1V vaccine is supported by an international partnering arrangement that includes the United Kingdom and Canada. The facilities performing the passive transfer model development studies are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. Human sera were collected under a research protocol approved by the USAMRMC Human Subjects Research Review Board and as part of an IRB- and HSRRB-approved clinical study titled, “A Phase 2(a), Dose-blinded, Block-Randomized Dose and Schedule Selection Study to Evaluate the Immunogenicity and Safety of the Recombinant Plague Vaccine rF1V in Healthy Volunteers” [Protocol rFV-02(a)].

PY - 2010/11/16

Y1 - 2010/11/16

N2 - Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

AB - Passive transfer models were developed to evaluate the ability of antibodies generated in cynomolgus macaques and humans vaccinated with a recombinant plague vaccine (rF1V) to protect naïve Swiss Webster mice against pneumonic plague. Development of the passive transfer model is intended to support clinical and nonclinical development of the rF1V vaccine. To evaluate protection, unfractionated serum collected from rF1V vaccinated cynomolgus macaques and human volunteers with known antibody titers to rF1, rV and rF1V was transferred into naïve Swiss Webster mice via the intraperitoneal route. Results of these studies demonstrated that passive immunization protected mice from challenge or extended mean survival time and that the passive transfer assay can be used to evaluate the functional role of antibodies induced by rF1V vaccination in protection against aerosol exposure.

KW - Passive transfer

KW - Pneumonic plague

KW - RF1V vaccine

KW - Yersinia pestis

UR - http://www.scopus.com/inward/record.url?scp=78349312669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349312669&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.09.062

DO - 10.1016/j.vaccine.2010.09.062

M3 - Article

C2 - 20920572

AN - SCOPUS:78349312669

SN - 0264-410X

VL - 28

SP - 7748

EP - 7756

JO - Vaccine

JF - Vaccine

IS - 49

ER -

Protection in mice passively immunized with serum from cynomolgus macaques and humans vaccinated with recombinant plague vaccine (rF1V)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this